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Introduction
Mycophenolate mofetil, an ester prodrug of
mycophenolic acid that acts by inhibiting the synthesis
of purines, has been advocated as a novel drug for acute
graft rejection.1 It can speciﬁcally suppress proliferation
of T and B lymphocytes, theoretically leaving
haemopoiesis and polymorphonuclear neutrophil
number and activity unchanged; this feature has been
presented as a major advantage over azathioprine.1
Mycophenolate mofetil reduced acute rejections of
organ transplantation in animals2 and in people in open-
label studies that also included ciclosporin.3,4 Three large
registration trials found that mycophenolate mofetil
reduced acute rejection by 30 to 50% compared with
azathioprine5,6 or placebo7 at 6 months after
transplantation. These ﬁndings served to launch
mycophenolate mofetil as part of standard treatment for
preventing rejection of transplanted kidneys and, more
recently, of heart, liver, lung, and bone marrow.8
Nowadays, this drug is used by most transplant centres
worldwide as part of maintenance immunosuppression
regimens.
However, since the introduction of mycophenolate
mofetil, a microemulsion preparation of ciclosporin,
Neoral (Novartis, Basel, Switzerland), has become
available. Because it is more rapidly, completely, and
reproducibly absorbed than Sandimmune (Novartis,
Basel, Switzerland), Neoral has become the preferred
form of ciclosporin in many centres.9–11 Whether
mycophenolate mofetil retains its better antirejection
activity over azathioprine with the present
microemulsion preparation of ciclosporin has not
been tested. Nor is solid evidence available on whether,
in view of current protocols, steroids still have a
fundamental role in maintenance immuno-
suppression regimens. Because of the well recognised
adverse effects of long-term steroid use, withdrawal 
of steroids at some point after transplantation is
desirable. Attempts to do so have been made,12–23
but results have been disappointing so far. The
beneﬁts of low-dose or no-steroid protocols included
less growth retardation in children,12 and reductions 
in hypertension,13,14 dyslipidaemia.15,16 and glucose
intolerance,16 but also more rejections18,19 so some of
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Summary
Background Mycophenolate mofetil has replaced azathioprine in immunosuppression regimens worldwide to
prevent graft rejection. However, evidence that its antirejection activity is better than that of azathioprine has been
provided only by registration trials with an old formulation of ciclosporin and steroid. We aimed to compare the
antirejection activity of these two drugs with a new formulation of ciclosporin.
Methods The mycophenolate steroids sparing multicentre, prospective, randomised, parallel-group trial compared
acute rejections and adverse events in recipients of cadaver-kidney transplants over 6-month treatment with
mycophenolate mofetil or azathioprine along with ciclosporin microemulsion (Neoral) and steroids (phase A), and
over 15 more months without steroids (phase B). The primary endpoint was occurrence of acute rejection episodes.
Analysis was by intention to treat.
Findings 168 patients per group entered phase A. 56 (34%) assigned mycophenolate mofetil and 58 (35%) assigned
azathioprine had clinical rejections (risk reduction [RR] on mycophenolate mofetil compared with azathioprine
13·7% [95% CI –25·7% to 40·7%], p=0·44). 88 patients in the mycophenolate mofetil group and 89 in the
azathioprine group entered phase B. 14 (16%) taking mycophenolate mofetil and 11 (12%) taking azathioprine had
clinical rejections (RR –16·2%, [–157·5% to 47·5%], p=0·71). Average per-patient costs of mycophenolate mofetil
treatment greatly exceeded those of azathioprine (phase A €2665 [SD 586] vs €184 [62]; phase B €5095 [2658] vs €322
[170], p<0·0001 for both).
Interpretation In recipients of cadaver kidney-transplants given ciclosporin microemulsion, mycophenolate mofetil
offers no advantages over azathioprine in preventing acute rejections and is about 15 times more expensive.
Standard immunosuppression regimens for transplantation should perhaps include azathioprine rather than
mycophenolate mofetil, at least for kidney grafts.
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the trials had to be prematurely stopped for safety
reasons.19
The mycophenolate steroids sparing (MYSS) study—a
multicentre, randomised, parallel-group trial—was
designed to clarify whether mycophenolate mofetil is
better than azathioprine in regimens that include
ciclosporin microemulsion, and whether it offers
advantages over azathioprine in the opportunity to
reduce or stop steroids. Our aim was to compare the
risk-beneﬁt proﬁle of mycophenolate mofetil and
azathioprine combined with this form of ciclosporin,
with or without concomitant steroid therapy. 
Methods
Patients 
Eligible patients were men and women aged 18–70 years
who were to receive a ﬁrst kidney transplant from a
cadaver donor. We excluded those with a history of
malignant disorders (apart from successfully treated
non-metastatic basal or squamous-cell carcinoma of 
the skin), serological evidence of infection with HIV 
or hepatitis B virus, systemic infections requiring
continued antibiotic therapy, haematological abnor-
malities (white-blood-cell count <3109/L, platelet count
<11011/L, or haemoglobin <50 g/L), severe gastroin-
testinal disorders, active peptic-ulcer disease, or inability
to take oral medication long term, pregnant women,
nursing mothers, women who did not agree to use
adequate contraception, and patients who did not fully
understand the purposes of the study or were already
involved in other studies. All patients selected provided
written informed consent according to the Declaration
of Helsinki. The study protocol was approved by the
ethics committees of all participating centres. 
Study design
The study was organised in two sequential phases:
phase A, from kidney transplantation to 6 months
afterwards; and phase B, from months 6 to 21 after
transplantation (ﬁgure 1). In phase A, selected patients
were randomly assigned equally within each centre to
receive treatment with 1 g mycophenolate mofetil twice
daily, or azathioprine once daily according to
bodyweight (100 mg if bodyweight <75 kg, 150 mg if
75 kg). Both treatments were started within the ﬁrst
3 days after transplantation, as soon as intestinal transit
was restored. Randomisation was centralised at the
Laboratory of Biostatistics of the Clinical Research
Centre for Rare Diseases Aldo e Cele Daccò of the Mario
Negri Institute for Pharmacological Research, under the
responsibility of an independent investigator who was
not involved in design or performance of the study.
Ciclosporin microemulsion and steroids were given
concomitantly to all patients as maintenance immuno-
suppressive therapy. From day of transplantation (day 0)
to day 3, ciclosporin (5 mg/kg daily) was infused
intravenously. From day 4, ciclosporin microemulsion
(10 mg/kg daily) was given orally in two divided 
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Figure 1: Trial proﬁle
 1 not transplanted 168 randomised to 
         mycophenolate mofetil
336 randomised to phase A
269 excluded
168 randomised to
         azathioprine     
 1 not transplanted
15 endpoints or dropouts 167 entering phase A 167 entering phase A 23 endpoints or dropouts
64 not entering phase B 152 completing phase A 
      
144 completing phase A 55 not entering phase B
26 endpoints or dropouts  88 entering phase B  89 entering phase B 30 endpoints or dropouts 
 62 completing phase B  59 completing phase B
605 screened for eligibility
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doses. The dose of intravenous or oral ciclosporin was
adjusted to maintain trough blood concentrations within
250–440 g/L from days 0 to 7, within 200–300 g/L
from days 8 to 28, and within 150–250 g/L up to 
study end. The steroid regimen was intravenous
methylprednisolone from days 0 to 4 (500 mg on day 0,
200 mg on days 1 and 2, 150 on day 3, and 100 mg on
day 4), oral prednisone (75 mg on day 5 and 50 mg on
day 6), then oral methylprednisolone (20 mg daily from
days 7 to 11, 16 mg daily from days 12 to 60, 12 mg daily
from days 61 to 120 and 8 mg daily up to end of phase
A). No patient was given induction therapy.
At the completion of phase A, patients entered phase
B if they had had no more than two acute rejection
episodes and no episodes of steroid-resistant rejection
during phase A, had stable serum creatinine
concentrations (changes 30% over the last 3 months of
phase A), and had a serum creatinine concentration of
177 mol/L or less and a urinary protein excretion rate
less than 1g per 24 h at the end of phase A (ﬁgure 1). In
these patients, the steroid dose was progressively
tapered and discontinued over the next 90 days. From
days 181 to 225 after transplantation, oral prednisone
was progressively tapered to 8 mg every other day, and
from days 226 to 270 the dose was further reduced to
2 mg every other day. The steroid was then
discontinued. If an acute rejection episode was
diagnosed, oral steroid was renewed at the dose
preceding the last reduction (if the patient was in the
tapering phase) or at 6 mg every other day (if the patient
had already discontinued the medication). The steroid
doses were then maintained up to study end. All
patients were also maintained on their previous (phase
A) dose of mycophenolate mofetil or azathioprine. Oral
ciclosporin was adjusted to maintain trough blood
concentrations within 150–250 g/L up to study end. 
For all patients, serum creatinine concentration was
monitored according to each centre’s practice up to
discharge and every month until study end. For those
entering phase B, serum creatinine was measured
weekly during the steroid-tapering protocol and for at
least 2 months after steroid discontinuation, every
2 weeks over the next 4 months, and every month up to
study end. Concentrations of ciclosporin in blood were
measured daily for the ﬁrst 15 days after transplantation,
and every month thereafter. Blood samples were taken
just before (trough concentration or C0) and 2 h after
(C2) the morning dose of ciclosporin microemulsion.
Other routine clinical and laboratory measurements
were made monthly as per each centre’s practice.
Additional assessments were done whenever deemed
clinically appropriate.
Acute rejection episodes were diagnosed if three or
more of these criteria were present: temperature 38°C or
higher without obvious signs of infection; graft swelling;
graft tenderness; a rise of 26·5 mol/L or more in serum
creatinine concentration in the presence of low or
therapeutic ciclosporin trough concentrations; oliguria;
increased resistive index on doppler ultrasonography; and
clinical response to steroid treatment consistent with
rejection. Kidney biopsy samples were taken whenever
appropriate to conﬁrm the diagnosis, and for all steroid-
resistant rejection episodes. The treatment of rejection
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Mycophenolate Azathioprine 
mofetil (n=168) (n=168)
Recipients
Men 119 (71%) 101 (60%)
Age (years) 43·3 (12·9) 45·9 (11·5)
Weight (kg) 67·2 (11·9) 66·2 (11·3)
Primary cause of renal failure
Diabetes mellitus 0 2 (1%)
Hypertension, renovascular disease 9 (5%) 11 (7%)
Glomerulonephritis 72 (43%) 64 (38%)
Polycystic kidney disease 16 (10%) 18 (11%)
Pyelonephritis/interstitial nephritis 20 (12%) 22 (13%)
Other 11 (7%) 12 (7%)
Uncertain 40 (24%) 38 (23%)
Donors
Men 96 (57%) 97 (58%)
Age (years) 43·5 (16·6) 43·1 (15·9)
Weight (kg) 70·1 (12·0) 70·9 (11·3)
B-cell crossmatch
Negative 163 (97%) 162 (96%)
Positive 1 (1%) 1 (1%)
Not done 4 (2%) 5 (3%)
HLA A, B, or Dr mismatches
0 3 (2%) 6 (4%)
1 42 (25%) 40 (24%)
2 71 (42%) 82 (49%)
3 45 (27%) 33 (20%)
Missing 7 (4%) 7 (4%)
Data are number (%) or mean (SD). 
Table 1: Baseline characteristics of phase A patients
Overall Mycophenolate Azathioprine p
mofetil
Acute rejection episodes
Clinical diagnosis 114 (34%) 56 (34%) 58 (35%) 0·91
Biopsy proven 68 (20%) 30 (18%) 38 (23%) 0·34
Steroid resistant 27 (8%) 9 (5%) 18 (11%) 0·11
Refractory* 4 (1%) 2 (1%) 2 (1%) 0·99
Banff score 2 66 (20%) 28 (17%) 38 (23%) 0·22
Adverse events
Deaths 8 (2%) 4 (2%) 4 (2%) 0·99
Delayed graft function 111 (33%) 52 (31%) 59 (35%) 0·49
White blood-cell count 54 (16%) 32 (19%) 22 (13%) 0·18
<3·5109/L
Platelet count 7 (2%) 2 (1%) 5 (3%) 0·45
<60109/L
Anaemia 22 (7%) 10 (6%) 12 (7%) 0·82
Diarrhoea 4 (1%) 3 (2%) 1 (1%) 0·99
Urinary tract infection 17 (5%) 11 (7%) 6 (4%) 0·32
CMV reactivations 85 (25%) 43 (26%) 42 (25%) 0·99
Ganciclovir-treated 79 (24%) 40 (24%) 39 (23%) 0·99
Pneumocystis carinii 1 (1%) 0 1 (1%) 0·99
pneumonia
Systemic candidosis 10 (3%) 4 (2%) 6 (4%) 0·75
CMV=cytomegalovirus. Data are number (%). *Resulting in graft loss despite rescue
therapy.
Table 2: Patients with events on phase A
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episodes was initially intravenous pulse steroids
(methylprednisolone, 500 mg daily for 3 days, tapered to
maintenance dose over 10 days). Biopsy-proven steroid-
resistant rejections were treated by intravenous infusion
of antilymphocyte immunoglobulins or monoclonal
antibodies to CD3 (OKT3) according to each centre’s
practice.
The MYSS study was designed as a superiority trial
according to data available at the time the protocol was
ﬁnalised.6 The primary efﬁcacy outcome was occurrence
of acute rejection episodes (clinically diagnosed). Sample
size was calculated on the basis of the frequency of events
expected in the two treatment groups during phase A. On
the basis of the results of the Tricontinental
Mycophenolate Mofetil Renal Transplantation Study,6 a
48% frequency of acute rejections was predicted in the
control group assigned azathioprine, and a 33% reduction
(eg, from 48% to 32%) was expected in the experimental
group assigned mycophenolate mofetil. To give the study
80% power to detect a statistically signiﬁcant (p<0·05)
reduction, and accounting for a predicted 13% dropout
rate, 168 patients per group had to be randomised.
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Figure 2: Clinically diagnosed (upper) and biopsy-proven (lower) acute rejection episodes during phase A
MMF=mycophenolate mofetil. AZA=azathioprine.
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Statistical analysis
Primary and secondary endpoints were analysed by
intention to treat. Analyses were based on the full
analysis set (ie, all patients randomly assigned the 
study medications), excluding two patients who were
randomised but did not undergo transplantation. The
hazard ratio for the primary endpoint and its 95% CI
was calculated by a Cox’s regression model, which
included the site as a covariate. The risk reduction 
was obtained as a percentage equal to: (1–hazard
ratio)100. Survival curves were based on Kaplan-
Meier estimates. 
Results
336 patients (168 per group) were randomly assigned.
Table 1 shows patients’ and donors’ characteristics at
randomisation. Cold ischaemia time was 16·3 h (SD
6·6) in the mycophenolate mofetil group and 16·1 h
(7·6) in the azathioprine group. Two patients (one per
group) did not receive the transplant for technical
reasons. Thus, 334 patients (167 per group) received the
study drugs. A similar proportion of patients in both
groups (52 [31%] mycophenolate mofetil vs 59 [35%]
azathioprine, p=0·42) had delayed recovery of renal
function and required one or more dialysis sessions in
the post-transplantation period. Four of these patients
(one assigned mycophenolate mofetil and three
assigned azathioprine) did not recover renal function
and remained dependent on dialysis.
Phase A
145 rejections were clinically diagnosed in 114 (34%) 
of the 334 patients entering phase A. 87 had only 
one episode and 27 two or more. 89 (61%) of the
clinically diagnosed rejections were also biopsy proven.
The proportion of patients with clinical or biopsy-proven
rejection episodes (table 2), time-courses to ﬁrst 
acute (clinical or biopsy-proven) rejection (ﬁgure 2),
mean Banff scores of all biopsy-proven rejections
(mycophenolate mofetil 3·23 [SD 0·19], azathioprine
3·63 [0·12], p=0·12), and occurrence of rejections 
with Banff score of 2 or more (table 2) did not differ
signiﬁcantly. The average doses of mycophenolate
mofetil and azathioprine in patients with or without
rejections were similar (data not shown).
All rejections were initially treated with intravenous
steroids. 87 patients (76%) recovered with steroids, 
but 27 (24%) needed rescue therapy with intravenous
immunoglobulins or OKT3. Four (15%) of the 
patients with steroid-resistant rejections did not
recover despite rescue therapy, and irreversible graft
loss resulted. There was a non-signiﬁcant trend
towards fewer steroid-resistant rejections in the
mycophenolate mofetil group, but the number of 
graft losses due to refractory rejection was identical in
the two groups (table 2). Serum creatinine
concentrations and creatinine clearance at different
www.thelancet.com Vol 364   August 7, 2004 507
Figure 3: Creatinine clearance values (upper) and serum creatinine
concentrations (lower) at different visits during phase A
Error bars indicate SE.
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Figure 4: C2 and C0 concentrations at different visits during phase A
Error bars indicate SE.
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time points were similar in the two groups (ﬁgure 3).
C0 and C2 values were also similar in the two 
groups (ﬁgure 4), as were the proportions of patients
who had C0 and C2 values in target ranges (data not
shown).
Four patients per group died. Overall, the frequency
and severity of adverse events were similar in the two
groups (table 2). Leucopenia episodes were more
frequently reported for the azathioprine group than for
the mycophenolate mofetil group (31 [19%] vs 13 [8%],
p=0·006). However, the cases with white-blood-cell
counts less than 3·5109/L showed an opposite trend,
and the number of patients with at least one white-
blood-cell count less than 3·5109/L (table 2) was
similar in the two groups (22 [13%] vs 32 [19%], p=0·18).
Thrombocytopenia was very uncommon in both groups
(table 2). Average white-blood-cell and platelet counts
did not differ between the treatment groups during the
early phases of the study. In the long term, however, the
white-blood-cell counts were higher for mycophenolate
mofetil and the platelet counts were higher for
azathioprine (ﬁgure 5). Throughout the observation
period the average daily doses of the two drugs were
more or less constant (ﬁgure 5).
An identical proportion of patients in the two
treatment groups had at least one episode of
cytomegalovirus reactivation and received ganciclovir
therapy (table 2). The average duration of the episodes
(mycophenolate mofetil 21·0 [3·5] days, azathioprine
25·8 [4·9] days, p=0·40) and of ganciclovir therapy
(mycophenolate mofetil 21·4 [11·9] days, azathioprine
24·2 [4·6] days, p=0·12) was similar in the two groups.
Phase B
177 (60%) of the 296 patients completing phase A
entered phase B of the trial (ﬁgure 1 and table 3). 
Cold ischaemia time was similiar in those assigned
mycophenolate mofetil (16·0 h [6·5]) and those 
assigned azathioprine (15·1 h [6·7]). Of the remaining
119 patients, 67 (56%) did not enter phase B (35 of
mycophenolate mofetil and 32 of azathioprine groups)
because they did not satisfy the inclusion criteria. 
The remaining 52 (44%) were not included because 
of safety concerns (eight and six), consent withdrawal,
or non-compliance (nine and three), protocol violations
(four and four), need for medications prohibited by 
the study protocol (three and four), adverse events
(three and two), or for other practical reasons (two 
and four). 
25 (14%) of the 177 patients entering phase B had 
one clinical diagnosis of acute rejection. In 12 (7%) of
the patients the rejections were biopsy proven. The
frequency of clinical rejections and of biopsy-proven
rejections (table 4), time courses to ﬁrst (clinical or
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Figure 5: Doses of study drugs, white blood cell counts, and platelet counts at different visits during phase A
MMF=mycophenolate mofetil. AZA=azathioprine. Error bars indicate SE.
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Mycophenolate mofetil
Azathioprine
(months)Time since transplantation (days)
Mycophenolate Azathioprine
mofetil (n=88) (n=89)
Recipients
Men 61 (69) 55 (62)
Age (years) 41·3 (12·1) 45·5 (11·8)
Weight (kg) 67·0 (12·4) 65·3 (11·6)
Primary cause of renal failure
Diabetes mellitus 0 1 (1%)
Hypertension, renovascular disease 4 (5%) 6 (7%)
Glomerulonephritis 40 (45%) 36 (40%)
Polycystic kidney disease 7 (8%) 11 (12%)
Pyelonephritis/interstitial nephritis 10 (11%) 12 (14%)
Other 5 (6%) 6 (7%)
Uncertain 22 (25%) 17 (19%)
Donors
Men 54 (61%) 55 (62%)
Age (years) 40·8 (16·9) 41·3 (16·0)
Weight (kg) 69·0 (11·8) 70·7 (10·5)
B-cell crossmatch
Negative 88 (100%) 88 (99%)
Positive 0 1 (1%)
Not done 0 0 
HLA A, B, or Dr mismatches
0 1 (1%) 4 (4%)
1 25 (28%) 20 (22%)
2 42 (48%) 46 (52%)
3 20 (23%) 19 (21%)
Missing 0 0
Data are number (%) or mean (SD).
Table 3: Baseline characteristics of phase B patients
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biopsy-proven) rejection (ﬁgure 6), mean Banff scores of
all biopsy proven-rejections (mycophenolate mofetil
3·00 [SD 1·41], azathioprine 3·00 [0·89], p=0·99), and
frequency of rejections with a Banff score of 2 or more
did not differ signiﬁcantly between the two groups
(table 4).
All rejections were initially treated with intravenous
steroids. 24 (96%) rejection episodes recovered with
steroids. One (4%) steroid-resistant rejection arose in
the mycophenolate mofetil group and resulted in
irreversible graft loss despite rescue therapy. Serum
creatinine concentrations were similar in the two groups
up to study end (table 5), as were creatinine clearance
and C0 and C2 values (data not shown). 
No patient died during phase B. The overall frequency
and severity of adverse events were similar in the two
groups. However, more patients in the azathioprine
group had at least one episode of leucopenia (white-
blood-cell count <3·5109/L) after steroid withdrawal
(table 4). No patient had severe thrombocytopenia or
anaemia. 11 (6%) had at least one opportunistic
infection. Eight cytomegalovirus reactivations (four
mycophenolate mofetil and four azathioprine) arose in
seven patients (four mycophenolate mofetil and three
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Figure 6: Clinically diagnosed (upper) and biopsy-proven (lower) acute rejection episodes during phase B
MMF=mycophenolate mofetil. AZA=azathioprine. 
0
0·1
0·2
0·3
0·4
0·5
0·6
0·7
0·8
0·9
1·0
Number at risk 
AZA 
MMF 
0·0
0·1
0·2
0·3
0·4
0·5
0·6
0·7
0·8
0·9
1·0
0 60 9030 120 150 180 210 240 270 300 330 360
0
89
88
86
87
84
83
84
79
76
73
68
68
68
67
65
64
64
64
64
63
64
63
61
63
60
62
 Number at risk 
AZA 
MMF 
89
88
86
87
84
83
84
79
76
73
68
68
68
67
65
64
64
64
64
63
64
63
61
63
60
62
60 9030 120 150 180 210 240 270 300 330 360
Risk reduction=216·20% (95% CI –157·50 to 47·50), p=0·71 
Risk reduction=11·00% (95% CI –179·00 to 71·60), p=0·84
Cu
m
ul
at
iv
e 
re
je
ct
io
n-
fr
ee
 p
ro
ba
bi
lit
y
Cu
m
ul
at
iv
e 
re
je
ct
io
n-
fr
ee
 p
ro
ba
bi
lit
y
Time since transplantation (days)
MMF: 14 events
AZA: 11 events
MMF: 6 events
AZA: 6 events
Articles
azathioprine). Three of these patients received
ganciclovir treatment (table 4). The two groups had
similar mean durations of episodes (mycophenolate
mofetil 131·7 [SD 232·2], median 18·0 days,
azathioprine 43·5 [18·3], median 27·5 days, p=0·48)
and of ganciclovir therapy (mycophenolate mofetil 17·5
[3·5] days, azathioprine 26·5 [12·0] days, p=0·42). 
Estimated costs of treatment 
Mean (SD) daily doses of mycophenolate mofetil and
azathioprine were 1893 (188) mg and 106 (22) mg for
phase A, and 1760 (410) mg and 89 (24) mg for phase B,
respectively. The cost of 1 mg mycophenolate mofetil
and azathioprine is €0·0081 and €0·0103, respectively.
Thus, the estimated costs of 1 day of mycophenolate
mofetil versus azathioprine treatment were €15·3
versus €1·1 and €14·3 versus €0·92 during phase A and
phase B, respectively. 
In phase A there were 163 patients in the
mycophenolate mofetil group and 163 in the
azathioprine group with available information. Their
mean treatment duration was 173 (34) days and 167 (45)
days, respectively. Thus, the average costs for
mycophenolate mofetil versus azathioprine treatment
for phase A patients were €2665 (586) versus €184 (62)
(p<0·0001). Overall treatment costs were €434 368 for
the mycophenolate mofetil group and €30 053 for the
azathioprine group.
In phase B there were 88 patients in the
mycophenolate mofetil group and 89 in the azathioprine
group with available information. Their average
treatment duration was 351 (157) days and 347 (153)
days, respectively. Thus, for phase B patients the average
costs for mycophenolate mofetil were €5095 (2658)
versus €322 (170) for azathioprine treatment
(p<0·0001). The overall treatment costs were €448 416
for the mycophenolate mofetil group and €27 716 for the
azathioprine group. The overall estimated costs for the
whole study period (phase A plus phase B) were
€882 784 for the mycophenolate mofetil group and
€57 770 for the azathioprine group.
Discussion
Mycophenolate mofetil was no better than azathioprine
in limiting acute rejection episodes. Graft losses due to
refractory rejections and adverse events did not differ
between the treatment groups. These ﬁndings suggest
that mycophenolate mofetil does not have a better risk-
beneﬁt proﬁle than azathioprine, even in the setting of a
dual immunosuppressive regimen that does not include
oral steroids. Of note, there were fewer acute rejections
in our controls than in controls from similar studies that
compared the same two drugs in the context of
conventional immunosuppressive regimens.5,6,13,20,21 By
contrast, the occurrence of acute rejections in the
mycophenolate mofetil group was similar in the present
and previous series.5,6
In previous studies comparing mycophenolate 
mofetil and azathioprine in a regimen including
ciclosporin Sandimmune, average trough ciclosporin
concentrations at different times after transplantation
were not given.5,6 In our protocol, we used a well deﬁned
scheme for ciclosporin dosing that was targeted to
trough blood concentrations of this drug.24 This scheme
was based on the results of a logistic regression model
generated to predict the trough concentrations
associated with low occurence of rejection and
negligible toxicity.24 Most patients in the MYSS study
had trough ciclosporin concentrations within the target
range (330–430 g/L) soon after transplantation, and
these patients had fewer rejections.25 Thus, the
achievement of target concentrations in most patients
could explain the low frequency of rejection in our
series, particularly for controls assigned azathioprine
treatment. Our present results, however, do not exclude
the possibility that mycophenolate mofetil provides
better antirejection activity in those patients whose
target ciclosporin concentrations are not achieved, at
least over the ﬁrst days post-transplantation. 
An additional important ﬁnding of our study was that
both drugs were equally well tolerated, with similar
occurrences of cytomegalovirus reactivation in the two
treatment groups. In particular, although leucopenia
was more common in the azathioprine group, there
was no objective evidence of more bone-marrow
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Overall Mycophenolate Azathioprine p
mofetil
Acute rejection episodes
Clinical diagnosis 25 (14%) 14 (16%) 11 (12%) 0·64
Biopsy proven 12 (7%) 6 ( 7%) 6 (7%) 0·78
Steroid resistant 1 (1%) 1 (1%) 0 0·49
Refractory* 1 (1%) 1 (1%) 0 0·49
Banff score 2 11 (6%) 5 (6%) 6 (7%) 0·98
Adverse events
White blood-cell count 38 (21%) 13 (15%) 25 (28%)  0·05
<3·5109/L
Diarrhoea 1 (1%) 1 (1%) 0 0·49
Urinary-tract infection 1 (1%) 0 1 (1%) 0·99
CMV reactivations 7 ( 4%) 4 (5%) 3 (3%) 0·62
Ganciclovir-treated 3 (2%) 2 (2%) 1 (1%) 0·62
Systemic mycosis 1 (1%) 0 1 (1%) 0·99
CMV=cytomegalovirus. Data are number (%). *Resulting in graft loss despite rescue
therapy.
Table 4: Patients with events on phase B
Mycophenolate Azathioprine p
mofetil
Time since transplantation (weeks)
25 121·1 (33·6) 118·5 (30·9) 0·66
44 129·1 (34·5) 122·9 (38·0) 0·32
64 122·9 (28·3) 119·3 (30·1) 0·53
84 125·5 (30·1) 121·1 (33·6) 0·54
Data are mean (SD).
Table 5: Serum creatinine concentration (mol/L) in patients
throughout phase B
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toxicity for azathioprine than for mycophenolate
mofetil.
These ﬁndings challenge the current practice of most
transplant centres to regard mycophenolate mofetil as a
key component of immunosuppressive drug regimens
based on ciclosporin microemulsion. Since the costs for
standard treatment with mycophenolate mofetil exceed
those for azathioprine by 15 times (€5416 vs €354 per
patient during both phase A and B), if azathioprione
were used instead of mycophenolate mofetil, more then
€4000 per patient per year could be saved. With a
population of 14 888 renal transplant patients in Europe
and 12 630 in the USA in 2002 (Council of Europe,
International data on organ donation, transplantation
and waiting list, 2002), and treatment costs for the two
drugs similar to those we have calculated, use of
azathioprione rather than mycophenolate mofetil
should give a net yearly saving of about €75 million in
Europe and US$77 million in the USA.
Whether, as suggested,26 mycophenolate mofetil might
have a role in reducing late allograft loss independently
of its effect on acute rejection remains to be proved. In
view of the cost, standard immunosuppression
regimens for transplantation should perhaps include
azathioprine rather than mycophenolate mofetil, at least
for kidney grafts. 
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